---
title: Smartphone Flicker Fusion Test for Patients With Optic Disorders.
nct_id: NCT03475147
overall_status: RECRUITING
phase: NA
sponsor: Randy Kardon
study_type: INTERVENTIONAL
primary_condition: Scotoma
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03475147.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03475147"
ct_last_update_post_date: 2025-11-24
last_seen_at: "2026-05-12T07:30:05.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Smartphone Flicker Fusion Test for Patients With Optic Disorders.

**Official Title:** Validation of a Smartphone-Based Flicker Fusion Test

**NCT ID:** [NCT03475147](https://clinicaltrials.gov/study/NCT03475147)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 500
- **Lead Sponsor:** Randy Kardon
- **Conditions:** Scotoma
- **Start Date:** 2017-01-27
- **Completion Date:** 2028-01-01
- **CT.gov Last Update:** 2025-11-24

## Brief Summary

The purpose of this project is to validate a quick, easy-to-use and administer smartphone flicker fusion test. The app (called eyeFusion) can potentially be used to easily and quickly collect critical flicker fusion measurements on patients admitted with optic disorders as part of the clinical care process.

## Detailed Description

The smartphone app developed is a flicker fusion that presents the subject with a series of stimuli consisting of a flickering pattern of bars above or below a static rectangle. For each stimulus presentation, the user has to tap the region that is flickering. The duration of the app is less than 2 minutes.

This study will assess the validity of the test construct in measuring flicker fusion thresholds, and serve as a foundation for further iterative designs of the app and future validation and characterization studies.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

Control

* Age matched 18-80 years of age.
* Healthy normal controls with no known eye disorders.

Exclusion Criteria:

* Scotoma or any other ocular disorder

Inclusion Criteria - Patients

* Age 18-80
* Clinically associated scotoma

Exclusion Criteria - Patients

-Any other ocular disorder
```

## Arms

- **eyeFusion Control Subjects** (ACTIVE_COMPARATOR) — Healthy normal controls with no known eye disorders age 18-80.
- **eyeFusion Patients** (EXPERIMENTAL) — Scotoma subjects aged 18-80.

## Interventions

- **eyeFusion** (DEVICE) — Smartphone app based flicker fusion test.

## Primary Outcomes

- **Assess Validity of the test construct measuring flicker fusion thresholds.** _(time frame: 1/1/2020)_ — The smartphone app developed is a flicker fusion that presents the subject with a series of stimuli consisting of a flickering pattern of bars above or below a static rectangle. The study will assess the validity of the test construct in measuring flicker fusion thresholds, and serve as a foundation for further iterative designs of the app and future validation and characterization studies.

## Locations (1)

- University of Iowa, Iowa City, Iowa, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of iowa|iowa city|iowa|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03475147.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03475147*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*